Alexei Shir

888 total citations
20 papers, 738 citations indexed

About

Alexei Shir is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Alexei Shir has authored 20 papers receiving a total of 738 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Molecular Biology, 7 papers in Oncology and 7 papers in Immunology. Recurrent topics in Alexei Shir's work include RNA Interference and Gene Delivery (10 papers), Virus-based gene therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Alexei Shir is often cited by papers focused on RNA Interference and Gene Delivery (10 papers), Virus-based gene therapy research (6 papers) and Immunotherapy and Immune Responses (6 papers). Alexei Shir collaborates with scholars based in Israel, Germany and United States. Alexei Shir's co-authors include Alexander Levitzki, Manfred Ogris, Ernst Wagner, Raymond Kaempfer, Yona Banai, Wolfgang Rödl, Efrat Flashner-Abramson, Menashe Bar‐Eli, Hadas Reuveni and Kirill Makedonski and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Nature Biotechnology.

In The Last Decade

Alexei Shir

19 papers receiving 715 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Alexei Shir Israel 12 547 187 148 100 79 20 738
Jay S. Lillquist United States 15 499 0.9× 157 0.8× 160 1.1× 131 1.3× 80 1.0× 23 857
Thomas Grussenmeyer Germany 15 360 0.7× 201 1.1× 166 1.1× 99 1.0× 47 0.6× 29 690
Monideepa Roy United States 11 779 1.4× 69 0.4× 251 1.7× 87 0.9× 113 1.4× 18 1.1k
Luba Benimetskaya United States 16 718 1.3× 97 0.5× 109 0.7× 68 0.7× 124 1.6× 22 861
Mo Zhou China 14 732 1.3× 94 0.5× 184 1.2× 74 0.7× 133 1.7× 24 955
Vigdis Sørensen Norway 18 741 1.4× 107 0.6× 67 0.5× 67 0.7× 71 0.9× 28 991
Maike Busch Germany 13 465 0.9× 78 0.4× 208 1.4× 86 0.9× 148 1.9× 40 819
Martin Loignon Canada 17 604 1.1× 71 0.4× 272 1.8× 79 0.8× 117 1.5× 29 866
Petra Pfisterer Germany 15 406 0.7× 229 1.2× 86 0.6× 145 1.4× 109 1.4× 18 803
Jinbiao Zhan China 13 258 0.5× 109 0.6× 170 1.1× 38 0.4× 65 0.8× 29 541

Countries citing papers authored by Alexei Shir

Since Specialization
Citations

This map shows the geographic impact of Alexei Shir's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexei Shir with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexei Shir more than expected).

Fields of papers citing papers by Alexei Shir

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexei Shir. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexei Shir. The network helps show where Alexei Shir may publish in the future.

Co-authorship network of co-authors of Alexei Shir

This figure shows the co-authorship network connecting the top 25 collaborators of Alexei Shir. A scholar is included among the top collaborators of Alexei Shir based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexei Shir. Alexei Shir is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shir, Alexei, Shoshana Klein, Idit Sagiv-Barfi, et al.. (2017). S101, an Inhibitor of Proliferating T Cells, Rescues Mice From Superantigen-Induced Shock. The Journal of Infectious Diseases. 217(2). 288–297. 3 indexed citations
2.
Shir, Alexei, et al.. (2017). PSMA-targeted polyinosine/polycytosine vector induces prostate tumor regression and invokes an antitumor immune response in mice. Proceedings of the National Academy of Sciences. 114(52). 13655–13660. 10 indexed citations
3.
Zigler, Maya, Alexei Shir, Shoshana Klein, et al.. (2016). HER2-Targeted Polyinosine/Polycytosine Therapy Inhibits Tumor Growth and Modulates the Tumor Immune Microenvironment. Cancer Immunology Research. 4(8). 688–697. 8 indexed citations
4.
Goshen‐Lago, Tal, Alexei Shir, Jonah Beenstock, et al.. (2015). Intrinsically active variants of Erk oncogenically transform cells and disclose unexpected autophosphorylation capability that is independent of TEY phosphorylation. Molecular Biology of the Cell. 27(6). 1026–1039. 35 indexed citations
5.
Flashner-Abramson, Efrat, Shiri Klein, Gerard E. Mullin, et al.. (2015). Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling. Oncogene. 35(20). 2675–2680. 35 indexed citations
6.
Zigler, Maya, Neta Pessah, Shoshana Klein, et al.. (2014). Optimization of Liganded Polyethylenimine Polyethylene Glycol Vector for Nucleic Acid Delivery. Bioconjugate Chemistry. 25(9). 1644–1654. 11 indexed citations
7.
Reuveni, Hadas, Efrat Flashner-Abramson, Lilach Steiner, et al.. (2013). Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment. Cancer Research. 73(14). 4383–4394. 101 indexed citations
8.
Zigler, Maya, Alexei Shir, & Alexander Levitzki. (2013). Targeted cancer immunotherapy. Current Opinion in Pharmacology. 13(4). 504–510. 25 indexed citations
9.
Abourbeh, Galith, Alexei Shir, Eyal Mishani, et al.. (2012). PolyIC GE11 polyplex inhibits EGFR‐overexpressing tumors. IUBMB Life. 64(4). 324–330. 49 indexed citations
10.
Shir, Alexei, Alexander Levitzki, Ernst Wagner, Shoshana Klein, & Manfred Ogris. (2011). Nucleic Acid-Based Therapeutics for Glioblastoma. Anti-Cancer Agents in Medicinal Chemistry. 11(8). 693–699.
11.
Shir, Alexei, Manfred Ogris, Wolfgang Röedl, Ernst Wagner, & Alexander Levitzki. (2010). EGFR-Homing dsRNA Activates Cancer-Targeted Immune Response and Eliminates Disseminated EGFR-Overexpressing Tumors in Mice. Clinical Cancer Research. 17(5). 1033–1043. 28 indexed citations
12.
Schaffert, David, Wolfgang Rödl, Alexei Shir, et al.. (2010). Poly(I:C)-Mediated Tumor Growth Suppression in EGF-Receptor Overexpressing Tumors Using EGF-Polyethylene Glycol-Linear Polyethylenimine as Carrier. Pharmaceutical Research. 28(4). 731–741. 72 indexed citations
13.
Levitzki, Alexander & Alexei Shir. (2010). Targeting the immune system to cancer. Polymers for Advanced Technologies. 22(1). 99–102. 1 indexed citations
14.
Shir, Alexei, Manfred Ogris, Ernst Wagner, & Alexander Levitzki. (2007). Correction: EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice. PLoS Medicine. 4(8). e266–e266. 1 indexed citations
15.
Shir, Alexei, Manfred Ogris, Ernst Wagner, & Alexander Levitzki. (2005). EGF Receptor-Targeted Synthetic Double-Stranded RNA Eliminates Glioblastoma, Breast Cancer, and Adenocarcinoma Tumors in Mice. PLoS Medicine. 3(1). e6–e6. 82 indexed citations
16.
Shir, Alexei, et al.. (2004). RNA molecules as anti-cancer agents. Seminars in Cancer Biology. 14(4). 223–230. 26 indexed citations
17.
Shir, Alexei, et al.. (2003). Tumor specific activation of PKR as a non-toxic modality of cancer treatment. Seminars in Cancer Biology. 13(4). 309–314. 6 indexed citations
18.
19.
Shir, Alexei & Alexander Levitzki. (2002). Inhibition of glioma growth by tumor-specific activation of double-stranded RNA–dependent protein kinase PKR. Nature Biotechnology. 20(9). 895–900. 53 indexed citations
20.
Shir, Alexei & Alexander Levitzki. (2001). Commentary: Gene Therapy for Glioblastoma: Future Perspective for Delivery Systems and Molecular Targets. Cellular and Molecular Neurobiology. 21(6). 645–656. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jay S. Lillquist Breakdown of academic impact, for papers by Thomas Grussenmeyer Breakdown of academic impact, for papers by Monideepa Roy Breakdown of academic impact, for papers by Luba Benimetskaya Breakdown of academic impact, for papers by Mo Zhou Breakdown of academic impact, for papers by Vigdis Sørensen Breakdown of academic impact, for papers by Maike Busch Breakdown of academic impact, for papers by Martin Loignon Breakdown of academic impact, for papers by Petra Pfisterer Breakdown of academic impact, for papers by Jinbiao Zhan
Rankless by CCL
2026